KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Intangibles: 2009-2022

Historic Change in Intangibles for Jazz Pharmaceuticals (JAZZ) over the last 9 years, with Dec 2022 value amounting to $25.0 million.

  • Jazz Pharmaceuticals' Change in Intangibles was N/A to $30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.9 million, marking a year-over-year change of. This contributed to the annual value of $25.0 million for FY2022, which is 39.74% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Change in Intangibles stood at $25.0 million for FY2022, which was up 39.74% from $17.9 million recorded in FY2021.
  • Jazz Pharmaceuticals' Change in Intangibles' 5-year high stood at $113.0 million during FY2020, with a 5-year trough of $17.9 million in FY2021.
  • Its 3-year average for Change in Intangibles is $52.0 million, with a median of $25.0 million in 2022.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Change in Intangibles soared by 40.37% in 2020 and then slumped by 84.17% in 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' Change in Intangibles (Yearly) stood at $111.1 million in 2018, then declined by 27.54% to $80.5 million in 2019, then spiked by 40.37% to $113.0 million in 2020, then crashed by 84.17% to $17.9 million in 2021, then spiked by 39.74% to $25.0 million in 2022.